Rapport Therapeutics, Inc. (NASDAQ:RAPP) Financings

Rapport Therapeutics, Inc.

Financings

RaiseDate
At-the-market programme of common stock
Closed: US$10M raised · US$25.05 a share
Nov 4, 2026
Public offering of common stock and pre-funded warrants
Closed: US$175M raised · US$21 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), BTIG (co-lead), Citizens Capital Markets (co-lead)
Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes
Nov 2, 2026
2.25% convertible senior notes due 2032
Closed: US$172.5M raised · Morgan Stanley +2
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead)
Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes
Nov 2, 2026
Private placement of common stock
Closed: US$30M raised · US$21 a share · Morgan Stanley +2
Dealers: Morgan Stanley, Leerink Partners, Evercore ISI
Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes
Nov 2, 2026
Public offering of common stock
Update: about US$250M · US$26 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Stifel (co-lead)
Sep 9, 2025

Read by 6ix AI from the company's releases